Ghisallo Capital Management
TRDA icon

Ghisallo Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Ghisallo Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,000
Closed -$141K – 293
2022
Q1 		$141K Hold
15,000
– – 0.02% 285
2021
Q4 		$257K Buy
+15,000
New +$364K 0.01% 429

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Ghisallo Capital Management's TRDA Position: Q2 2022 in Review

Ghisallo Capital Management sold out of Entrada Therapeutics (TRDA) in Q2 2022, closing a stake of 15,000 shares — an estimated $141K sold.

Ghisallo Capital Management first reported a position in TRDA in Q4 2021 and held it in 2 quarters. The position peaked at $257K in Q4 2021. 38 funds tracked by Wall St. Rank hold TRDA as of Q2 2022.

  • Ghisallo Capital Management reported no remaining Entrada Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ghisallo Capital Management sold 15,000 Entrada Therapeutics shares in Q2 2022, an estimated $141K.
  • Ghisallo Capital Management first reported a position in Entrada Therapeutics in Q4 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's Entrada Therapeutics position peaked at $257K in Q4 2021.
  • 38 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2022.

Based on Ghisallo Capital Management's 13F filing for Q2 2022, filed 9 Aug 2022.